Ryan Haumschild, PharmD, MS, MBA, CPEL

Video content above is prompted by the following: When health care systems move to biosimilar adoption, what are the key structural and operational considerations that go into this transition? Source link Ryan Haumschild, PharmD, MS, MBA, CPEL

Video content above is prompted by the following: What are the key gaps in communication between academic and community centers regarding the use of bispecifics, and how can they be bridged? (Ms Chang) What best practices have you seen for

Opinion Video February 14, 2025 Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.

Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you. Source link Ryan Haumschild, PharmD, MS, MBA, CPEL

Opinion Video February 14, 2025 Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences

Video content above is prompted by the following: What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics? Source link Ryan Haumschild,

Video content above is prompted by the following: What are the clinical implications of these trials, and which unmet needs are being addressed or potentially fulfilled in the CLL landscape? Source link Ryan Haumschild, PharmD, MS, MBA, CPEL

Video content above is prompted by the following: Biosimilars have been shown to reduce costs for patients and the healthcare system in general. Given that, why do you think the uptake of biosimilars is still relatively low? How can the

Video content above is prompted by the following: There is a wealth of exciting data emerging from ASH 2024 on bispecific therapies for B-cell lymphomas. Before we discuss these new findings, which bispecific therapies were already available for B-cell lymphomas?

Video content above is prompted by the following: Coming into ASH 2024, what would you consider to be the largest unmet needs in the treatment and management of CLL and MCL? Provide an overview of the following emerging BTKi treatment